Tyme Technologies, Inc. (TYME): Price and Financial Metrics


Tyme Technologies, Inc. (TYME): $1.29

-0.03 (-2.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TYME Stock Price Chart Interactive Chart >

Price chart for TYME

TYME Price/Volume Stats

Current price $1.29 52-week high $4.99
Prev. close $1.32 52-week low $0.85
Day low $1.28 Volume 1,215,600
Day high $1.31 Avg. volume 7,457,445
50-day MA $1.44 Dividend yield N/A
200-day MA $1.46 Market Cap 222.15M

Tyme Technologies, Inc. (TYME) Company Bio


Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.


TYME Latest News Stream


Event/Time News Detail
Loading, please wait...

TYME Latest Social Stream


Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | June 14, 2021

Tyme Technologies, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Tyme Technologies, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | June 11, 2021

Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results

Tyme Technologies, Inc. (Nasdaq:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results.

Yahoo | June 10, 2021

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

Photo by peterschreiber.media/iStock via Getty Images Tyme Technologies (TYME) continues to be a below-par investment to date, yet, I still trust my "bamboo investment” approach will yield significant gains as the company begins to report pivotal trial readouts for their SM-88 product in pancreatic cancer. Furthermore, I believe the company’s...

Biologics on Seeking Alpha | May 29, 2021

TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET

TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today announced that it will host a conference call and live video webcast on Thursday, June 10, 2021 at 5:00 PM ET. The Company will report its fiscal year 2021 financial results and provide a business update that same day.

Yahoo | May 26, 2021

Read More 'TYME' Stories Here

TYME Price Returns

1-mo -5.15%
3-mo -39.44%
6-mo 11.21%
1-year -4.80%
3-year -63.66%
5-year N/A
YTD 5.74%
2020 -12.86%
2019 -62.06%
2018 -42.16%
2017 70.13%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7494 seconds.